Flora Growth (FLGC) Proxy Filing summary

Executive summary

• The proxy filing details the 2024 Annual and Special Meeting, including key proposals for shareholder vote, such as director elections, auditor re-appointment, equity plan amendments, executive compensation, and a significant acquisition share issuance.

• The company is focused on expanding its pharmaceutical and consumer cannabis business, highlighted by the acquisition of TruHC Pharma GmbH, a German medical cannabis company with EU-GMP licenses.

• Management emphasizes the strategic rationale for the TruHC acquisition, aiming to strengthen its position in the German and EU cannabis markets and diversify revenue streams.

• The company faces ongoing challenges related to profitability, cash flow, and regulatory compliance, with a going concern warning from auditors.

Voting matters and shareholder proposals

• Election of four directors for a one-year term: Kevin Taylor, Clifford Starke, Edward Woo, and Brendan Cahill.

• Re-appointment of Davidson & Company LLP as independent auditors for 2024 and authorization for the board to set their remuneration.

• Amendment to the 2022 Incentive Compensation Plan to increase shares issuable from 950,000 to 2,500,000.

• Approval of stock appreciation rights (SARs) for the CEO and CFO, with vesting tied to substantial share price increases.

• Approval of the issuance of 635,363 shares to complete the acquisition of TruHC Pharma GmbH.

Board of directors and corporate governance

• Board consists of four directors, with three deemed independent under Nasdaq and Canadian rules.

• Board committees include Audit, Compensation, and Nominating & Corporate Governance, all chaired by independent directors.

• The company has adopted a Code of Conduct and Ethics and provides orientation and ongoing education for directors.

• Board diversity is limited, with no women directors or executive officers as of the latest filing.